Clonality and Genetic Divergence in Multifocal Low-Grade Superficial Urothelial Carcinoma as Determined by Chromosome 9 and p53 Deletion Analysis

Multifocality and recurrence are clinically important features of urothelial carcinomas of the urinary bladder. Recent molecular genetic studies have suggested that multifocal urothelial carcinomas are monoclonally derived from an identical transformed progenitor cell. However, most of these studies investigated advanced and poorly differentiated tumors. The study presented focuses on early papillary tumors, including 52 superficial well-differentiated multifocal and recurrent bladder carcinomas from 10 patients. Microdissection separating urothelium from stromal cells was considered essential to obtain pure tumor cell populations. Genetic analysis was carried out by applying two different methods. Dual color fluorescence in situ hybridization (FISH) with centromeric probes for chromosomes 9 and 17 and gene-specific probes for chromosome loci 9q22, 9p21, and 17p13 was carried out in parallel to loss of heterozygosity (LOH) analyses applying 5 microsatellite markers on these chromosomes. Overall, deletions on chromosome 9p were found in 47 tumors (90%), at chromosome 9q in 36 tumors (69%) and at chromosome 17p in 3 tumors (6%). There was a very high correlation of the results between FISH and LOH analysis. Ten early superficial papillary tumors showed deletion of chromosome 9p without deletion of 9q, suggesting 9p deletions as a very early event in the development of papillary urothelial carcinoma. Although in four patients, all investigated tumors showed identical genetic alterations and one patient showed no genetic alterations at the loci investigated, in five patients, two or more clones with different deletions were found. In four of these patients, the results are compatible with clonal divergence and selection of different cell subpopulations derived from a common progenitor cell. However, in one patient different alleles in two markers at chromosome 9 were deleted, favoring an independent evolution of two recurring tumor cell clones. In summary, we could show that there is considerable genetic heterogeneity in early multifocal and recurring urothelial carcinoma and demonstrated the occurrence of two independent clones in at least one patient as an indicator of possible initial oligoclonality of bladder cancer.

[1]  M. Knowles,et al.  A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: localization of the candidate region within a single 840 kb YAC. , 1997, Human molecular genetics.

[2]  S. Lerner,et al.  Role of chromosome 9 in human bladder cancer. , 1993, Cancer research.

[3]  N. Sternberg,et al.  Preparation and screening of an arrayed human genomic library generated with the P1 cloning system. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[4]  David Sidransky,et al.  Detection of bladder cancer recurrence by microsatellite analysis of urine , 1997, Nature Medicine.

[5]  R. Takahashi,et al.  Metachronous multifocal development of urothelial cancers by intraluminal seeding , 1993, The Lancet.

[6]  K. Nomoto,et al.  Prolongation of kidney graft survival by cyclophosphamide-induced tolerance in rats. , 1995, The Journal of urology.

[7]  T. Sekiya,et al.  Allelic loss on chromosome 9 in bladder cancer tissues and urine samples detected by blunt‐end single‐strand DNA conformation polymorphism , 1998, International journal of cancer.

[8]  J. Barrett,et al.  An Alu polymorphism intragenic to the TP53 gene. , 1991, Nucleic acids research.

[9]  B. Czerniak,et al.  Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia , 1997, Oncogene.

[10]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[11]  Kathleen R. Cho,et al.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.

[12]  P. Nieh,et al.  Biopsy of apparently normal urothelium in patients with bladder carcinoma. , 1978, The Journal of urology.

[13]  O. Yoshida,et al.  Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. , 1998, Cancer research.

[14]  Georgia Lahr,et al.  Identification of expressed genes by laser-mediated manipulation of single cells , 1998, Nature Biotechnology.

[15]  N. Kinukawa,et al.  p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[16]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[17]  D. Sidransky,et al.  Evidence for two bladder cancer suppressor loci on human chromosome 9. , 1993, Cancer research.

[18]  B. Vogelstein,et al.  Clonal origin of bladder cancer. , 1992, The New England journal of medicine.

[19]  F. Rousseau,et al.  Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31 , 1999, Oncogene.

[20]  Harlan I. Firminger,et al.  Atlas of tumor pathology , 1954 .

[21]  Z. Petrovich,et al.  Carcinoma of the bladder : innovations in management , 1997 .

[22]  R. Cote,et al.  Two molecular pathways to transitional cell carcinoma of the bladder. , 1994, Cancer research.

[23]  M. Knowles,et al.  Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. , 1999, Genomics.

[24]  A. Hartmann,et al.  Multiple mutation analyses in single tumor cells with improved whole genome amplification. , 1999, The American journal of pathology.

[25]  P. Carroll,et al.  Chromosome‐9 loss detected by fluorescence in situ hybridization in bladder cancer , 1995, International journal of cancer.

[26]  H Stepp,et al.  Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. , 1996, The Journal of urology.

[27]  J. Tomaszewski,et al.  Characterization of chromosome 9 deletions in transitional cell carcinoma by microsatellite assay. , 1993, Human molecular genetics.

[28]  I. Petersen,et al.  p53 mutations in phenacetin-associated human urothelial carcinomas. , 1993, Carcinogenesis.

[29]  L. Aaltonen,et al.  Semiautomated assessment of loss of heterozygosity and replication error in tumors. , 1996, Cancer research.

[30]  A Hofstetter,et al.  Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. , 1999, The American journal of pathology.

[31]  Y. Bignon,et al.  Human bladder cancers and normal bladder mucosa present the same hot spot of heterozygous chromosome‐9 deletion , 1998, International journal of cancer.

[32]  M. Knowles,et al.  Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. , 1994, Oncogene.

[33]  T. Wheldon,et al.  Clonal analysis of phenacetin‐implicated urothelial carcinoma , 1995, International journal of cancer.

[34]  P. Jones,et al.  Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. , 1996, Cancer research.

[35]  S. Rasheed,et al.  A simple procedure for maximum yield of high-quality plasmid DNA. , 1990, BioTechniques.

[36]  P. Nichols,et al.  Mosaicism in human epithelium: macroscopic monoclonal patches cover the urothelium. , 1995, The Journal of urology.

[37]  M. Soloway,et al.  Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. , 1989, Progress in clinical and biological research.

[38]  Education in Pathology Atlas of tumor pathology. Third series , 1991 .

[39]  A. Harris,et al.  Bladder cancer--field versus clonal origin. , 1992, The New England journal of medicine.

[40]  R. Hruban,et al.  Brief report: molecular biology and the early detection of carcinoma of the bladder--the case of Hubert H. Humphrey. , 1994, The New England journal of medicine.

[41]  I. N. Reid,et al.  Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  P. Jones,et al.  Molecular Genetics in Carcinoma of the Bladder , 1998 .

[43]  Y S Erozan,et al.  Molecular Detection of Primary Bladder Cancer by Microsatellite Analysis , 1996, Science.

[44]  D. Neal,et al.  c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder , 1992, The Lancet.

[45]  W. Catalona,et al.  Urothelial Tumors of the Urinary Tract , 1992 .